Background/Aims:
 Investigation of the efficacy adjuvant RT in cervical cancer stage I-IIA according to FIGO (2018) terms risk factors and oncologic outcomes.
 Methods: 
 The study included 113 patients with I-IIA. Patients who received external pelvic and/or intracavitary brachytherapy (ICBT) after surgery retrospectively analyzed for demographic data , histology, grade, tumor s...

The study was undertaken with an aim to determine the role of interstitial brachytherapy in the management of advanced malignancy of uterine cervix. Thirty six histologically proven patienls of certical cancer of stage III and IV, previously treated with either external beam radiotherapy or combined chemo and radiotherapy were takenfor the study between December 1995 and June 1999. All of the p...

This is a retrospective study, the organ doses to bladder and rectum were compared between Nucletron PLATO V14.2.3 (BV) newer version software Oncentra MasterPlan V4.3 (OMP) treatment planning systems (TPS). The data of 32 intracavitary brachytherapy patients at Hospital Universiti Sains Malaysia from January 2010 June 2015 used. These sets used for catheter reconstruction both OMP TPS followed...

 Introduction:The commercial 252Cf sources are too large in size and clinical applications of neutronbrachytherapy (NBT) are limited to a small number of intracavitary treatments of cervical cancers. Recently, under the Cooperative Research and Development Agreement (CRADA) with Isotron Inc., the Oak Ridge National Laboratory (ORNL) encapsulated a new medical 252Cf sources, cal...

BACKGROUND Concurrent chemoradiotherapy (EBRT + cisplatin) plus intracavitary brachytherapy is the standard of care in patients with advanced cervical cancer. However, a number of patients could not undergone brachytherapy due to massive residual tumor or anatomical distortion. In this study, we have evaluated the treatment outcome in patients with locally advanced cervical cancer, undergone co...

PURPOSE Radiotherapy with concurrent chemotherapy has been recommended as standard treatment for locally advanced cervical cancer. To validate the main tumor location before each high-precision helical tomotherapy (HT) fraction, the development of a more reliable marker or indicator is of clinical importance to avoid inadequate coverage of the main tumor. MATERIAL AND METHODS A 61-year-old wo...

BACKGROUND Intracavitary brachytherapy (ICBT) is usually applied as boost radiotherapy for superficial residual of nasopharyngeal carcinoma (NPC) after primary extern-beam radiptherapy (ERT). Here, we evaluated the outcome of endoscope-guided interstitial intensity-modulated brachytherapy (IMBT) boost radiation for deep-seated residual NPC. METHODOLOGY/PRINCIPAL FINDINGS Two hundred and thirt...

PURPOSE To identify organs at risk (OAR) and analyze the dose volume histograms (DVHs) for intracavitary brachytherapy in cancer of the cervix. Late toxicities are our concern in treatment of cancer cervix especially as it is presenting in younger age population. MATERIAL AND METHODS Patients with cancer of the cervix were treated using CT and MRI compatible, high dose rate, (HDR) applicators...

PURPOSE To retrospectively compare the potential dosimetric advantages of a multichannel vaginal applicator vs. a single channel one in intracavitary vaginal high-dose-rate (HDR) brachytherapy after hysterectomy, and evaluate the dosimetric advantage of fractional re-planning. MATERIAL AND METHODS We randomly selected 12 patients with endometrial carcinoma, who received adjuvant vaginal cuff ...